The primary outcome
4 mg/day
An increased prevalence of chronic kidney disease (CKD) [] could be a future burden in our society
27 July 2017
Ask a
Introduction
December 22, 2021: Emergency use authorization issued for treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death
Some patient factors also influence the decision to adjust drug doses, such as the degree of renal disease and patient size
or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis and rhabdomyolysis with acute renal failure secondary to myoglobinuria reported with HMG-CoA reductase inhibitors; may occur at any dose level, but are increased at the Return to One-Minute Consult Index
Objective To evaluate the efficacy and safety of high-intensity statin therapy in patients with chronic kidney disease (CKD)
Researchers also discovered that physicians were overprescribing the recommended dose of rosuvastatin, as determined by the FDA, to patients with advanced kidney disease
10 years or older: 10 mg orally once a day
atorvastatin will increase the level or effect of dabigatran by P-glycoprotein (MDR1) efflux transporter
Moderate to severe renal dysfunction (eGFR 15 to 59 mL/min/1